1 búsqueda de la palabra clave 'O6 methylguanine-DNA methyltransferase'

Treatment of pituitary neoplasms with temozolomide: a review / Luis Vicente Syro Moreno  

Público ISBD Título : Treatment of pituitary neoplasms with temozolomide: a review Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Cancer Idioma : Inglés (eng) Palabras clave : Temozolomide  pituitary carcinoma  pituitary adenoma  O6 methylguanine-DNA methyltransferase  MGMT  treatment Resumen : Temozolomide, an orally administered alkylating agent, is used to treat malignant gliomas. Recent reports also have documented its efficacy in the treatment of pituitary adenomas and carcinomas. Temozolomide methylates DNA and thereby exhibits an antitumor effect. O6‐methylguanine‐DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylating adducts induced by temozolomide, counteracting its effects. The authors of this review conducted a Medline database search regarding temozolomide in the treatment of pituitary tumors. Demographic characteristics, tumor types, and therapeutic responses were noted in all patients. Data regarding MGMT immunoexpression, which was documented in some studies, were correlated with information regarding clinical and radiologic responses. To date, there have been 19 reported cases of adenohypophyseal tumors treated with temozolomide, including 13 adenomas and 6 carcinomas. Ten of those 13 adenomas responded favorably, and 2 nonresponsive tumors had high‐level MGMT immunoexpression. All 6 carcinomas responded to therapy, but data regarding MGMT expression were available for only 3 patients, and each had low MGMT expression. In 2 adenomas, morphologic studies were performed both before and after the patients received temozolomide. The responsive tumor had necrosis, hemorrhage, fibrosis, and neuronal differentiation. The nonresponsive tumor had no changes. There have been no reported complications attributable to temozolomide. The current results indicated that temozolomide is efficacious in the treatment of aggressive pituitary adenomas and pituitary carcinomas. Evidence indicated that low‐level MGMT immunoexpression is correlated with a favorable response. A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Bernd W Scheithauer, Ricardo Lloyd, Queenie Lau, Ricardo Gonzalez, Humberto Uribe, Michael Cusimano, Kalman Kovacs, Eva Horvath Referencia : Cancer. 2011 Feb 1;117(3):454-62. DOI (Digital Object Identifier) : 10.1002/cncr.25413 PMID : 20845485 En línea : https://onlinelibrary.wiley.com/doi/10.1002/cncr.25413 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3576 Treatment of pituitary neoplasms with temozolomide: a review [documento electrónico] / Luis Vicente Syro Moreno,  . - 2011. Obra : Cancer Idioma : Inglés (eng) Palabras clave : Temozolomide  pituitary carcinoma  pituitary adenoma  O6 methylguanine-DNA methyltransferase  MGMT  treatment Resumen : Temozolomide, an orally administered alkylating agent, is used to treat malignant gliomas. Recent reports also have documented its efficacy in the treatment of pituitary adenomas and carcinomas. Temozolomide methylates DNA and thereby exhibits an antitumor effect. O6‐methylguanine‐DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylating adducts induced by temozolomide, counteracting its effects. The authors of this review conducted a Medline database search regarding temozolomide in the treatment of pituitary tumors. Demographic characteristics, tumor types, and therapeutic responses were noted in all patients. Data regarding MGMT immunoexpression, which was documented in some studies, were correlated with information regarding clinical and radiologic responses. To date, there have been 19 reported cases of adenohypophyseal tumors treated with temozolomide, including 13 adenomas and 6 carcinomas. Ten of those 13 adenomas responded favorably, and 2 nonresponsive tumors had high‐level MGMT immunoexpression. All 6 carcinomas responded to therapy, but data regarding MGMT expression were available for only 3 patients, and each had low MGMT expression. In 2 adenomas, morphologic studies were performed both before and after the patients received temozolomide. The responsive tumor had necrosis, hemorrhage, fibrosis, and neuronal differentiation. The nonresponsive tumor had no changes. There have been no reported complications attributable to temozolomide. The current results indicated that temozolomide is efficacious in the treatment of aggressive pituitary adenomas and pituitary carcinomas. Evidence indicated that low‐level MGMT immunoexpression is correlated with a favorable response. A significant proportion of pituitary adenomas and carcinomas had low MGMT immunoexpression. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Bernd W Scheithauer, Ricardo Lloyd, Queenie Lau, Ricardo Gonzalez, Humberto Uribe, Michael Cusimano, Kalman Kovacs, Eva Horvath Referencia : Cancer. 2011 Feb 1;117(3):454-62. DOI (Digital Object Identifier) : 10.1002/cncr.25413 PMID : 20845485 En línea : https://onlinelibrary.wiley.com/doi/10.1002/cncr.25413 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3576

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000146	AC-2011-031	Archivo digital	Producción Científica	Artículos científicos	Disponible